Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary careBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7391.707 (Published 29 March 2003) Cite this as: BMJ 2003;326:707
- Stephen Chapman, professor of prescribing studies (firstname.lastname@example.org)a,
- Elly Reeve, business managera,
- Giri Rajaratnam, director of health policy and public healthb,
- Richard Neary, consultant in medical biochemistryc
- a Department of Medicines Management, Keele University, Staffordshire ST5 5BG
- b North and South Stoke Primary Care Trusts, Stoke-on-Trent, ST4 4LX
- c North Staffordshire Hospital NHS Trust, Central Pathology Laboratory, Stoke-on-Trent ST4 7PA
- Correspondence to: S Chapman
To obtain maximum health benefits from a drug it is necessary to follow the pharmaceutical company's recommendations for use. However, variations in clinical prescribing practice and patient compliance mean that drugs are not always used under optimum conditions. One way of achieving maximum benefit could be to set up an “outcomes guarantee,” in which a pharmaceutical company and prescribing stakeholders (such as health authorities and primary care or hospital trusts) agree on the outcomes that they would expect from a drug in a given indication. If the drug fails to fulfil expectations, the pharmaceutical company refunds the health service for the cost of the drug. This encourages the pharmaceutical company to promote responsible prescribing and ensures that healthcare resources are not wasted on ineffective treatments. The National Institute for Clinical Excellence's shared risk policy for interferon beta in multiple sclerosis, and the subsequent commentary, has raised awareness of the potential for such schemes.1–5
In 1999, North Staffordshire Health Authority, Parke-Davis (now Pfizer), and Keele University entered a pilot collaboration to provide an outcomes guarantee for statins in lowering blood cholesterol concentrations. The health authority had identified cardiovascular disease as a local priority6 and was looking for ways to disseminate best practice without making excessive demands on itself or its general practitioners. The project enabled the health authority to work openly with a pharmaceutical company to achieve common goals and to share the risks of disseminating good clinical practice. In this article, we describe how the project, which was launched in 2000, was set up.
Under an outcomes guarantee, drug manufacturers agree to refund the health …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial